

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Balan, et al.

Serial No.: Not Yet Assigned

Group Art Unit No.:

Filed: Herewith

Examiner:

For: VANILLOID RECEPTOR LIGANDS AND THEIR USE
IN TREATMENTS

Docket No.: A-825

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form and provide(s) a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).


Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees, which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Please send all future correspondence to:

US Patent Operations/RVP
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

Respectfully submitted,



Richard V. Person
Attorney/Agent for Applicant(s)
Registration No.: 42,991
Phone: (805) 447-3299
Date: October 16, 2003


EXPRESS MAIL CERTIFICATE

Express Mail mail labeling number: EV 351338793 US

Date of Deposit: October 16, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sherry St. Andrew
Printed Name


Signature

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	A-825	Not Yet Assigned
	Applicant	
	Balan, et al.	
	Filing Date	Group
	October 16, 2003	

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1						
	A2						
	A3						
	A4						
	A5						
	A6						
	A7						
	A8						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	B1	WO 03/004023	16 Jan 2003	PCT				
	B2	WO 03./006438	23 Jan 2003	PCT				
	B3	WO 03/066595	14 Aug 2003	PCT				
	B4							
	B5							

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

	C1	Valenzano, et al., N-(4-Tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: I. In Vitro Characterization and Pharmacokinetic Properties, JPET, 306: 377-386 (2003)
	C2	Pomonis, et al., N-(4-Tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain, JPET, 306: 387-393 (2003)
	C3	
	C4	
	C5	
	C6	

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.